Impaired Endothelial Release of Tissue-Type Plasminogen Activator in Patients With Chronic Kidney Disease and Hypertension
Why the study?
Is the endothelial release of tissue-type plasminogen activator impaired in patients with chronic kidney disease and hypertension compared to healthy controls?
Population
9 nondiabetic, nonsmoking men with advanced chronic kidney disease and hypertension, and age-matched healthy…
Comparison
Intraarterial infusions of desmopressin… vs Age-matched healthy controls receiving the same…
Design
Case-control
Authors
Discussion
Loading...
Member takes
Implication
Impaired endothelial tPA release may heighten thrombotic risk in CKD hypertension; leaves open causal contribution and need for prospective trials.
Structured PICO
Is the endothelial release of tissue-type plasminogen activator impaired in patients with chronic kidney disease and hypertension compared to healthy controls?
P
Population
9 nondiabetic, nonsmoking men with advanced chronic kidney disease (glomerular filtration rate 11 to 28 mL/min x 1.73 m2; aged 33 to 75 years) and hypertension, and age-matched healthy controls.
I
Intervention
Intraarterial infusions of desmopressin, methacholine, and sodium nitroprusside given locally in the brachial artery.
C
Comparator
Age-matched healthy controls receiving the same intraarterial infusions.
O
Outcome
Stimulated net and total cumulated release of tissue-type plasminogen activator (tPA).surrogate
Patients with advanced chronic kidney disease and hypertension exhibit a markedly impaired capacity for acute endothelial release of tPA, potentially contributing to a defective local defense against arterial thrombosis.
Cite This Study
Hrafnkelsdóttir et al. (2004) studied this question.